
- The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of $23.09 to $24.56 on a day volume of 563.43 thousand shares, closed regular trading session at $24.26.
- The European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead candidate RINVOQ (upadacitinib 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation, as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI). AbbVie shares traded in a range of $139.05 to $146.3 on a day volume of 17.63 million shares, closed regular trading session at $143.51.